Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronie's Disease
Date:10/11/2010

ients.  XIAFLEX will be administered two times a week every six weeks for up to four treatment cycles (2 x 4).  Each treatment cycle will be followed by a penile modeling procedure.  Patients will be followed for 52 weeks post-first injection in the double-blind studies and for 36 weeks in the open label trial.  

The trials' co-primary endpoints are the change from baseline in the Peyronie's disease bother domain of the Peyronie's Disease Questionnaire (PDQ) compared to placebo and percent improvement from baseline in penile curvature compared to placebo.  The PDQ will have at least three domains, which will include Peyronie's disease bother, severity of psychological and physical symptoms of Peyronie's disease, and penile pain.  Safety measurements will include adverse event monitoring, immunogenicity testing and clinical labs.

"We are encouraged by the clinical profile of XIAFLEX, which emerged from our earlier phase IIb clinical trial in Peyronie's disease.  XIAFLEX was well-tolerated and produced clinically significant reductions in both penile curvature and disease bother," said Dr. Jim Tursi, Auxilium's Vice President of Clinical Research & Development.  "Over the last six months, our team, in conjunction with the U.S. Food and Drug Administration (FDA), outside experts and men with Peyronie's disease, has spent a considerable amount of time and effort to refine the PDQ, which has now been accepted for use in the phase III clinical trials by the FDA's Study Endpoint and Label Development (SEALD) Division."

Conference Call and WebcastAuxilium will hold a webcast and conference call today, October 11, 2010 at 8:30 a.m. ET, to:

  • discuss the initiation of the global phase III program of XIAFLEX for the treatment of Peyronie's disease; and
  • update the leading indicators for the launch of XIAFLEX in Dupuytren's contracture.

  • The presentation slides to be used during the cal
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
    8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
    9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
    10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
    (Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
    (Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
    ... Calif., Oct 21 MAP Pharmaceuticals, Inc. (Nasdaq: ... of Thomas P. McCracken as Vice President, Intellectual ... property program in support of the potential commercialization ... inhaled migraine therapy, and other product opportunities. ...
    ... (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer ... Backer, Ph.D., to the newly-created position of senior vice ... all aspects of chemistry, manufacturing and controls (CMC) in ... pipeline products. "We are extremely pleased to ...
    Cached Medicine Technology:MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 2MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 3Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations 2
    (Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
    (Date:4/22/2014)... rabbits, Johns Hopkins scientists have found a way to ... the development of atherosclerosis, the main cause of heart ... among humans. The condition develops when fat builds inside ... and hardened, greatly reducing their ability to feed oxygen-rich ... In a series of experiments, described April 7 in ...
    (Date:4/22/2014)... news release is available in German . ... are important intracellular signaling molecules, but their mode of ... aspects of cellular function and behavior, while at high ... membranes and DNA. To analyze how redox signaling unfolds ... optical microscopy technique has been developed jointly by the ...
    (Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
    (Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
    Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2
    ... novel pancreatic cancer vaccine shows promise in improving survival when ... University Hospitals Case Medical Center,s Seidman Cancer Center and Case ... was presented today (embargoed 11:00 am ET) at the Annual ... part of Digestive Disease Week in San Diego. ...
    ... thousands of psychiatrists attend their field,s largest annual meeting ... drug treatments report overwhelmingly on positive results. ... the Journal of Clinical Psychopharmacology by two ... University, who analyzed the presentations given at two recent ...
    ... The national gastroenterology societies have issued a new document ... Sedation Curriculum for Gastrointestinal Endoscopy (MSCGE) grew out ... to the training of procedure sedation. The document is ... of Gastroenterology , GIE:Gastrointestinal Endoscopy , Hepatology ...
    ... The Food and Drug Administration has approved a new ... disorders. The test, or assay, was developed by an expert ... Lawrence Schwartz, M.D., Ph.D., chair of the Division of ... Professor of Medicine at VCU, has spent more than 30 ...
    ... Lies Van Nieuwenhove, researcher at the Antwerp Institute of ... the sleeping sickness parasite. They can be used in ... dangerous parasites. Each year many thousands of ... parasite, a trypanosome, which is transmitted by the bite ...
    ... TUESDAY, May 22 (HealthDay News) -- Fear of spiders, a ... therapy session, according to a small new study. People ... hold a tarantula after a two- or three-hour therapy session, ... six months, the Northwestern University researchers reported. The lasting ...
    Cached Medicine News:Health News:Researchers present new findings for novel pancreatic cancer vaccine 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 3Health News:Gastroenterology Societies issue sedation curriculum for gastrointestinal endoscopy 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Better tests for sleeping sickness 2Health News:Spider-Phobes May Get Quick Relief 2
    ... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
    ... 1500 Sectioning System provides a versatile means ... plant tissues. The 1500 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effect ...
    ... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
    ... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
    Medicine Products: